Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIOL OTCMKTS:ENDV OTCMKTS:LENSF NASDAQ:STSS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOLBIOLASE$0.01$0.01$0.02▼$1.94$581K0.672.58 million shs42,369 shsENDVEndonovo Therapeutics$0.00+100.0%$0.00$0.00▼$0.00$240K-1.351.02 million shs3.67 million shsLENSFPresbia$0.02$0.02$0.00▼$0.19$257K5.915,650 shsN/ASTSSSharps Technology$5.77-0.7%$5.14$3.36▼$2,224.20$5.92M2.15398,736 shs14,650 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOLBIOLASE-1.09%-6.19%-1.09%-24.17%-88.63%ENDVEndonovo Therapeutics+100.00%-33.33%0.00%-33.33%-81.82%LENSFPresbia0.00%0.00%0.00%0.00%0.00%STSSSharps Technology-1.69%-1.02%+15.97%-39.48%+580,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIOLBIOLASE1.1114 of 5 stars3.50.00.00.01.10.00.0ENDVEndonovo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALENSFPresbiaN/AN/AN/AN/AN/AN/AN/AN/ASTSSSharps Technology0.8448 of 5 stars0.03.00.00.02.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIOLBIOLASE 3.00Buy$1.2013,086.81% UpsideENDVEndonovo Therapeutics 0.00N/AN/AN/ALENSFPresbia 0.00N/AN/AN/ASTSSSharps Technology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIOLBIOLASE$48.83M0.01N/AN/A($0.07) per share-0.13ENDVEndonovo Therapeutics$10K24.13$0.02 per share0.01($0.08) per share0.00LENSFPresbiaN/AN/AN/AN/AN/AN/ASTSSSharps TechnologyN/AN/AN/AN/A$110.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIOLBIOLASE-$20.63M-$14.94N/A∞N/A-41.65%-1,782.73%-55.31%8/6/2025 (Estimated)ENDVEndonovo Therapeutics-$2.80MN/A0.00∞N/AN/AN/AN/AN/ALENSFPresbiaN/AN/A0.00∞N/AN/AN/AN/AN/ASTSSSharps Technology-$9.30M-$1,881.93N/A∞N/AN/A-98.77%-53.85%N/ALatest ENDV, BIOL, STSS, and LENSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025STSSSharps TechnologyN/A$38.62N/A$38.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIOLBIOLASEN/AN/AN/AN/AN/AENDVEndonovo TherapeuticsN/AN/AN/AN/AN/ALENSFPresbiaN/AN/AN/AN/AN/ASTSSSharps TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIOLBIOLASEN/A0.710.36ENDVEndonovo TherapeuticsN/AN/AN/ALENSFPresbiaN/AN/AN/ASTSSSharps TechnologyN/A1.651.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIOLBIOLASE8.79%ENDVEndonovo TherapeuticsN/ALENSFPresbiaN/ASTSSSharps Technology17.17%Insider OwnershipCompanyInsider OwnershipBIOLBIOLASE0.27%ENDVEndonovo Therapeutics5.61%LENSFPresbia74.20%STSSSharps Technology1.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIOLBIOLASE16033.41 million33.32 millionNot OptionableENDVEndonovo Therapeutics11.21 billion1.14 billionNot OptionableLENSFPresbia2017.12 millionN/ANot OptionableSTSSSharps Technology31.02 million1.00 millionNot OptionableENDV, BIOL, STSS, and LENSF HeadlinesRecent News About These CompaniesSharps Technology Inc. Stock Grades | STSS | Barron'sJuly 17 at 7:17 AM | barrons.comSharps Technology Appoints Paul Danner as Executive ChairmanJuly 9, 2025 | theglobeandmail.comSharps Technology Inc. Company & People | STSS | Barron'sJune 29, 2025 | barrons.comSharps Technology Inc News (STSS) - Investing.comJune 26, 2025 | investing.comSharps Technology Advances Shipment Under $50 Million SoloGard Supply Agreement and Begins Manufacturing Facility UpgradesJune 18, 2025 | globenewswire.comSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 11, 2025 | markets.businessinsider.comSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 11, 2025 | financialpost.comFSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 11, 2025 | globenewswire.comSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 10, 2025 | financialpost.comFSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 10, 2025 | globenewswire.comSharps Technology, Inc. CEO Robert Hayes to Present at Virtual Investor Summit on June 10, 2025June 9, 2025 | quiverquant.comQSharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025June 9, 2025 | globenewswire.comSharps Technology stock soars on first commercial shipmentsJune 4, 2025 | investing.comSharps Technology Shares Rise After New Shipments BeginJune 4, 2025 | marketwatch.comSharps Technology Begins Shipping Smart Safety SyringesJune 4, 2025 | tipranks.comSharps Technology, Inc. Begins Commercial Shipments of Smart Safety Syringes, Marking Revenue Generation MilestoneJune 4, 2025 | quiverquant.comQSharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase AgreementsJune 4, 2025 | globenewswire.comSharps Technology Regains Nasdaq ComplianceMay 22, 2025 | tipranks.comSharps Technology Regains Compliance with Nasdaq Minimum Bid Price Listing RuleMay 22, 2025 | globenewswire.comSharps Technology, Inc. CEO Robert Hayes to Present at Aegis Capital Corp. 2025 Virtual Conference on May 22May 21, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENDV, BIOL, STSS, and LENSF Company DescriptionsBIOLASE NASDAQ:BIOL$0.0091 0.00 (0.00%) As of 07/17/2025BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.Endonovo Therapeutics OTCMKTS:ENDV$0.0002 +0.00 (+100.00%) As of 01:33 PM EasternEndonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.Presbia OTCMKTS:LENSF$0.02 0.00 (0.00%) As of 10/21/2022Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.Sharps Technology NASDAQ:STSS$5.77 -0.04 (-0.69%) Closing price 04:00 PM EasternExtended Trading$5.86 +0.09 (+1.49%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
